Phase 2 N=100 Oral Azithromycin Versus Doxycycline in Posterior Blepharitis
Posterior Blepharitis
Primary: Change of Blepharitis Symptoms Score — 1.8; 2.8 score — p=0.03
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=150 Chalazion Conservative Treatment Trial
Chalazion Unspecified Eye, Unspecified Eyelid · Chalazion Left Eye, Unspecified Eyelid · Chalazion Right Eye, Unspecified Eyelid
Primary: Number of Participants With Complete Resolution — 13; 12; 11 participants
Phase 4 N=30 Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for the Management of Acute Blepharitis
Blepharitis
Primary: Improvement in Signs and Symptoms of Blepharitis — 15; 15 participants
Phase 2 N=70 Treatment of Patients With Blepharitis and Facial Rosacea
Blepharitis · Meibomianitis · Dry Eye
Primary: Change in Bulbar Conjunctival Hyperemia — -0.61; -0.60 Scores on a scale — p=0.578
Phase 2 N=129 Evaluation of AXR-270 for the Treatment of Posterior Blepharitis Associated With Meibomian Gland Dysfunction
Posterior Blepharitis · Meibomian Gland Dysfunction
Primary: Adverse Events — 1; 1; 2; 0 adverse events
N/A N=38 To Compare Blephapad Combo vs Standard Treatment for Eyelid Cleansing in Bilateral Posterior Blepharitis
Bilateral Blepharitis (Disorder)
Primary: Percentage Change of the Total Score of the Grading Scales for Meibomian Gland Dysfunction (MGD) — -38.5; -29.9 percentage of change in the total score
N/A N=139 Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye
Chalazion · Dry Eye Syndromes
Primary: Meibomian Gland Assessment (Total Meibomian Gland Secretion Score) — 6.3; 5.6; 14.3; 6.1 Scores on a scale
Phase 2 N=75 Topical IL-1-Ra for Treatment of Posterior Blepharitis
Posterior Blepharitis
Primary: Meibomian Gland Secretion Quality — 1.7; 1.7; 1.8 Units on a scale
Phase 1 N=17 Demodex Blepharitis Treatment Study
Chronic Blepharitis
Primary: Change in the Number of Demodex Mites — -3; -0.4 Mites
Phase 2 N=36 Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis
Blepharitis
Primary: COHORT 1 and 2 COMBINED: Mean Change From Baseline to Day 14 in the Composite (Sum) Score of Signs & Symptoms of Blepharitis — -2.0; -1.2 units on a scale — p=0.0471
Phase 2 N=224 Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension for the Treatment of Blepharitis
Blepharitis
Primary: Percentage of Study Eyes With Complete Cure (Score 0) of Blepharitis Signs and Symptoms at Day 15 — 4; 2 study eyes — p=0.4434
Phase 3 N=50 Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction
Chalazion · Dry Eye Syndromes
Primary: Association Between Screening Methods (Meibomian Gland Expression) and Treatment Effectiveness Outcomes (Total Meibomian Gland Score) — 0.4816 Correlation coefficient…
N/A N=19 Intense Pulse Light Treatment With Meibomian Gland Expression of the Upper Eyelids in Dry Eye Disease
Dry Eye
Primary: Non-invasive Tear Break up Time (TBUT) — 3.9; 4.0 seconds
N/A N=14 Meibomian Gland Dysfunction Treatment
Meibomian Gland Dysfunction · Dry Eye
Primary: Dry Eye Questionnaire 5 (DEQ-5) Score — 11.8; 11.8 score on a scale — p=0.02
Phase 2 N=93 Efficacy and Safety Assessment of Azyter® Eye Drops (T1225) in Patients With Blepharitis
Blepharitis
Primary: Visual Analogue Scale (VAS - Ranges 0-100 mm) — 36.5; 28.5 units on a scale (from 0 to 100 mm) — p=0.072
N/A N=20 Efficacy of IPL Treatment of Dry Eye and Ocular Rosacea
Ocular Rosacea · Dry Eye
Primary: Change in Ocular Surface Disease Index (OSDI) Symptom Survey Score — -25.9; -2.0 percentage of change in OSDI score — p=0.0312
Phase 4 N=60 Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis
Meibomian Gland Dysfunction · Posterior Blepharitis
Primary: Ocular Surface Disease Index — 56.6; 46.4; 48.4 units on a scale
N/A N=200 Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Meibomian Gland Dysfunction · Dry Eye
Primary: Stage 1 Mean Change in Total Meibomian Gland Score From Baseline to 3 Months — 11.6; 4.5 units on a scale — p=<0.0001
Phase 4 N=31 Lipids of the Human Tear Film and Their Effect on Tear Stability
Blepharitis
Primary: Global Response to Therapy — 16; 41 eyes — p=.001
Phase 3 N=558 Comparative Study to Evaluate ISV-305 Compared to Vehicle in Blepharitis Subjects
Active, Symptomatic Blepharitis
Primary: Number of Participants in the ITT Population With a Reduction in the Day 1 (Baseline) Total Clinical Signs and Symptom Score by at Least 2 Units at Day 15 With No…
N/A N=55 Treatment of Meibomian Gland Dysfunction and Dry Eye in Contact Lens Wearers
Meibomian Gland Dysfunction · Dry Eye
Primary: Mean Change in Meibomian Gland Score From Baseline at 3 Months — 12.4; 1.4 units on a scale — p=<0.0001
N/A N=8 IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD
GVHD · Ocular Rosacea · Dry Eye Syndrome
Primary: Number of Participants Who Responded to Intense Pulsed Light (IPL) — 5; 2 participants
Phase 4 N=162 Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora
Bacterial Conjunctivitis
Primary: Susceptability Changes in Streptococcus Pneumoniae Distal to the Site of Instillation — 0; 0; 0; 0 Percent of resistant isolates
N/A N=26 Mechanisms of Light-based Therapies for Dry Eye Disease
Dry Eye Syndromes · Meibomian Gland Dysfunction
Primary: Change From Baseline in Non-invasive Tear Break Up Time to the Final Follow-up 3 Months After Final Treatment Session — -2.61; -0.85 seconds
Phase 2 N=95 Safety, Efficacy and Pharmacokinetics of CBT-008 in Patients With Meibomian Gland Dysfunction
Meibomian Gland Dysfunction
Primary: IOP Related to Safety — 15.906; 16.452; 16.469 mmHg
Phase 4 N=30 Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers
Dry Eye
Primary: Efficacy of Lifitegrast Ophthalmic Solution 5% in Treating the Symptoms of Dry Eye in Contact Lens Wearers as Measured by Change in Total CLDEQ-8 Score From Baseline to…
Phase 3 N=421 Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis
Blepharitis
Primary: Proportion of Participants Cured Based on a Collarette Score at Day 43. — 0.439; 0.072 Proportion cured
Phase 4 N=81 Artificial Tears, Tear Lipids and Tear Film Dynamics
Dry Eye
Primary: Tear Lipid Layer Thickness — 0.72; -7.58; 2.06; 1.41 nm
N/A N=69 The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction
Meibomian Gland Dysfunction
Primary: Tear Film Breakup Time — 4.65; 4.42 seconds — p=0.550
N/A N=21 Evaluate the Safety and Effectiveness of The Tixel Fractional System in the Treatment of Meibomian Gland Disfunction
Dry Eye Syndromes · Dry Eye · Meibomian Gland Dysfunction
Primary: Score and Change From Baseline in Tear Break Up Times (TBUT), as Assessed by a Masked Rater — 4.0; 1.9; 3.4; 4.7 seconds